Abstract
There are not effective therapies for metastatic unresectable, non-radioactive iodine (RAI)-avid thyroid carcinomas. Fortunately, thyroid carcinomas represent a promising paradigm for targeted therapy due to the presence of activating mutations of genes coding the kinase
tyrosines that are involved in all functions of cancer cells (such as growth or invasion). In this paper, an efficacy and toxicity of sorafenib, one of the multi-kinase inhibitors in thyroid carcinomas treatment, is presented.
Abstract
There are not effective therapies for metastatic unresectable, non-radioactive iodine (RAI)-avid thyroid carcinomas. Fortunately, thyroid carcinomas represent a promising paradigm for targeted therapy due to the presence of activating mutations of genes coding the kinase
tyrosines that are involved in all functions of cancer cells (such as growth or invasion). In this paper, an efficacy and toxicity of sorafenib, one of the multi-kinase inhibitors in thyroid carcinomas treatment, is presented.
To view the full article in PDF or eBook formats, please click on the icons above.
